Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have been given a consensus recommendation of “Moderate Buy” by the twenty-two research firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation, sixteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $1,008.96.

A number of analysts have commented on the stock. Bank of America boosted their price target on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research report on Friday, April 12th. Argus lifted their price target on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a research report on Tuesday. Royal Bank of Canada restated an “outperform” rating and issued a $1,229.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday. Evercore ISI began coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price target for the company. Finally, Sanford C. Bernstein started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price objective for the company.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $1,069.16 on Thursday. Regeneron Pharmaceuticals has a 12-month low of $684.80 and a 12-month high of $1,081.17. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The firm has a market capitalization of $117.81 billion, a price-to-earnings ratio of 31.59, a price-to-earnings-growth ratio of 2.21 and a beta of 0.13. The business has a 50 day simple moving average of $974.69 and a 200 day simple moving average of $947.43.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The business had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. On average, equities research analysts anticipate that Regeneron Pharmaceuticals will post 37.23 EPS for the current year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 756 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total value of $802,872.00. Following the transaction, the director now owns 1,382 shares in the company, valued at approximately $1,467,684. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, Director Bonnie L. Bassler sold 756 shares of the stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total value of $802,872.00. Following the transaction, the director now owns 1,382 shares in the company, valued at $1,467,684. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Michael S. Brown sold 1,535 shares of the firm’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $1,040.00, for a total transaction of $1,596,400.00. Following the transaction, the director now owns 1,382 shares in the company, valued at approximately $1,437,280. The disclosure for this sale can be found here. In the last ninety days, insiders sold 61,971 shares of company stock worth $61,217,654. 7.48% of the stock is currently owned by company insiders.

Institutional Trading of Regeneron Pharmaceuticals

Large investors have recently modified their holdings of the company. Eudaimonia Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals by 1.2% during the 4th quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company’s stock worth $803,000 after purchasing an additional 11 shares in the last quarter. Team Hewins LLC raised its position in Regeneron Pharmaceuticals by 2.5% in the 1st quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock valued at $434,000 after purchasing an additional 11 shares during the last quarter. Angeles Wealth Management LLC lifted its position in Regeneron Pharmaceuticals by 3.5% during the 1st quarter. Angeles Wealth Management LLC now owns 325 shares of the biopharmaceutical company’s stock worth $313,000 after buying an additional 11 shares in the last quarter. Drive Wealth Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 4.0% during the fourth quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 12 shares in the last quarter. Finally, MCF Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 12 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.